Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
29.31
-0.49 (-1.64%)
At close: Jun 6, 2025, 4:00 PM
29.40
+0.09 (0.31%)
After-hours: Jun 6, 2025, 5:32 PM EDT
Surmodics Employees
Surmodics had 389 employees as of September 30, 2024. The number of employees increased by 13 or 3.46% compared to the previous year.
Employees
389
Change (1Y)
13
Growth (1Y)
3.46%
Revenue / Employee
$312,532
Profits / Employee
-$51,062
Market Cap
420.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SRDX News
- 5 weeks ago - Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - Business Wire
- 5 weeks ago - Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - Business Wire
- 6 weeks ago - Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
- 2 months ago - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Business Wire
- 3 months ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 3 months ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters
- 4 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 4 months ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire